Immunotherapy for Lung Cancer: Mechanisms of Resistance and Response Strategy / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 112-123, 2021.
Artículo
en Chino
| WPRIM
| ID: wpr-880249
ABSTRACT
Inhibition of immune checkpoints is at the forefront of immunotherapy for lung cancer. However, a high percentage of lung cancer patients do not respond to these immunotherpy or their responses are transient, indicating the existence of immune resistance. Emerging evidence suggested that the interactions between cancer cells and immune system were continuous and dynamic. Here, we review how a range of cancer-cell-autonomous characteristics, tumor-microenvironment factors, and host-related influences account for heterogenous responses. Furthermore, with the identification of new targets of immunotherapy and development of immune-based combination therapy, we elucidate the methods might useful to overcome resistance.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Tipo de estudio:
Estudio pronóstico
Idioma:
Chino
Revista:
Chinese Journal of Lung Cancer
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS